• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.

作者信息

Muller William J, Madhi Shabir A, Seoane Nuñez Beatriz, Baca Cots Manuel, Bosheva Miroslava, Dagan Ron, Hammitt Laura L, Llapur Conrado J, Novoa Jose M, Saez Llorens Xavier, Grenham Amy, Kelly Elizabeth J, Mankad Vaishali S, Shroff Manish, Takas Therese, Leach Amanda, Villafana Tonya

机构信息

Northwestern University, Chicago, IL.

University of the Witwatersrand, Johannesburg, South Africa.

出版信息

N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5.

DOI:10.1056/NEJMc2214773
PMID:37018470
Abstract
摘要

相似文献

1
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.Nirsevimab用于预防足月儿和晚期早产儿的呼吸道合胞病毒感染
N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5.
2
Balanced on the Biggest Wave: Nirsevimab for Newborns.乘风破浪：尼氏单抗助力新生儿。
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.
3
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
4
Palivizumab for the prevention of respiratory syncytial virus infection.帕利珠单抗预防呼吸道合胞病毒感染。
Can Fam Physician. 2010 Aug;56(8):769-72.
5
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.哥伦比亚早产儿和婴儿使用帕利珠单抗预防呼吸道合胞病毒的成本-效用分析。
BMC Infect Dis. 2024 Apr 19;24(1):418. doi: 10.1186/s12879-024-09300-5.
6
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.尼氏病毒单抗免疫接种预防婴儿和儿童呼吸道合胞病毒相关下呼吸道感染（24 月龄以下）
Nurs Womens Health. 2024 Feb;28(1):75-79. doi: 10.1016/j.nwh.2023.11.002. Epub 2023 Dec 6.
7
Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.29-34 6/7 周早产儿在美国使用奈瑟单抗和帕利珠单抗预防呼吸道合胞病毒的成本效益。
Pediatr Neonatol. 2024 Mar;65(2):152-158. doi: 10.1016/j.pedneo.2023.04.015. Epub 2023 Sep 11.
8
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).从医学上脆弱的儿童中分离出的呼吸道合胞病毒株的分子和表型特征：尼司特韦单抗（MEDLEY）的 2/3 期随机、双盲、帕利珠单抗对照试验的探索性分析。
Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5.
9
Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.在呼吸道合胞病毒全年流行的环境中，帕利珠单抗对早产儿住院的有效性。
J Infect Dis. 2021 Jul 15;224(2):279-287. doi: 10.1093/infdis/jiaa749.
10
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.Nirsevimab 和帕利珠单抗给药后的 RSV 中和抗体。
Pediatrics. 2024 Nov 1;154(5). doi: 10.1542/peds.2024-067174.

引用本文的文献

1
Introduction to Respiratory Syncytial Virus.呼吸道合胞病毒简介
Methods Mol Biol. 2025;2948:1-17. doi: 10.1007/978-1-0716-4666-3_1.
2
Efficacy and Safety of Anti-Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab in Neonates: A Real-World Monocentric Study.抗呼吸道合胞病毒单克隆抗体尼塞韦单抗在新生儿中的疗效和安全性：一项真实世界单中心研究
Vaccines (Basel). 2025 Aug 6;13(8):838. doi: 10.3390/vaccines13080838.
3
Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.
初呼吸之外：通过母体免疫和婴儿免疫预防实现呼吸道合胞病毒的全面防控
Asian Biomed (Res Rev News). 2025 Jul 28;19(3):116-130. doi: 10.2478/abm-2025-0015. eCollection 2025 Jun.
4
Severe RSV Infection Occurring at the End of Nirsevimab's Protection Window: A Case Report.在尼塞韦单抗保护期结束时发生的严重呼吸道合胞病毒感染：一例报告
Case Rep Pediatr. 2025 Jul 21;2025:3334926. doi: 10.1155/crpe/3334926. eCollection 2025.
5
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.长效单克隆抗体预防呼吸道合胞病毒疾病应用的系统评价与专家共识：ARMADA（推进呼吸道合胞病毒管理与疾病认知）工作组
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
6
Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants.优化婴儿呼吸道合胞病毒预防干预措施的时机
JAMA Netw Open. 2025 Jul 1;8(7):e2522779. doi: 10.1001/jamanetworkopen.2025.22779.
7
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
8
Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned.呼吸道合胞病毒：健康负担、疾病预防与治疗——近期进展与经验教训
Microlife. 2025 Feb 10;6:uqaf003. doi: 10.1093/femsml/uqaf003. eCollection 2025.
9
Health-care burden related to respiratory syncytial virus in a resource-constrained setting: a prospective observational study.资源受限环境下呼吸道合胞病毒相关的医疗负担：一项前瞻性观察性研究。
Lancet Glob Health. 2025 Jun;13(6):e1072-e1081. doi: 10.1016/S2214-109X(25)00048-8.
10
Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections.在婴儿中普遍使用尼塞韦单抗：呼吸道合胞病毒相关下呼吸道感染的住院和儿科重症监护病房入院情况分析
Eur J Pediatr. 2025 May 16;184(6):345. doi: 10.1007/s00431-025-06125-5.